Creative Planning acquired a new position in shares of Qiagen (NYSE:QGEN – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 12,506 shares of the company’s stock, valued at approximately $563,000.
Several other institutional investors also recently bought and sold shares of QGEN. Raymond James & Associates grew its stake in Qiagen by 15.6% during the first quarter. Raymond James & Associates now owns 48,252 shares of the company’s stock worth $2,364,000 after buying an additional 6,517 shares during the period. Natixis Advisors L.P. purchased a new stake in Qiagen during the first quarter worth approximately $991,000. Dimensional Fund Advisors LP grew its stake in Qiagen by 26.5% during the first quarter. Dimensional Fund Advisors LP now owns 412,784 shares of the company’s stock worth $20,229,000 after buying an additional 86,591 shares during the period. Sei Investments Co. grew its stake in Qiagen by 24.9% during the first quarter. Sei Investments Co. now owns 31,235 shares of the company’s stock worth $1,530,000 after buying an additional 6,231 shares during the period. Finally, Vanguard Group Inc. grew its stake in Qiagen by 2.3% during the first quarter. Vanguard Group Inc. now owns 8,049,796 shares of the company’s stock worth $394,440,000 after buying an additional 179,913 shares during the period. 57.99% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
Several research analysts have recently weighed in on the stock. StockNews.com assumed coverage on shares of Qiagen in a research note on Thursday, October 5th. They issued a “buy” rating for the company. JPMorgan Chase & Co. decreased their target price on shares of Qiagen from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Tuesday. Citigroup restated a “buy” rating and issued a $60.00 target price on shares of Qiagen in a research note on Tuesday, September 26th. TheStreet downgraded shares of Qiagen from a “b-” rating to a “c+” rating in a research note on Thursday, September 14th. Finally, UBS Group decreased their target price on shares of Qiagen from $50.00 to $48.00 and set a “neutral” rating for the company in a research note on Wednesday, August 9th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $53.27.
Qiagen Trading Down 2.7 %
NYSE QGEN opened at $37.84 on Thursday. Qiagen has a 12 month low of $37.76 and a 12 month high of $51.18. The company has a debt-to-equity ratio of 0.38, a current ratio of 2.36 and a quick ratio of 1.96. The company has a market capitalization of $8.63 billion, a price-to-earnings ratio of 25.74, a price-to-earnings-growth ratio of 9.47 and a beta of 0.40. The company’s fifty day moving average price is $41.79 and its two-hundred day moving average price is $44.26.
Qiagen (NYSE:QGEN – Get Free Report) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.50 by $0.01. Qiagen had a net margin of 17.04% and a return on equity of 13.72%. The firm had revenue of $497.00 million for the quarter, compared to the consensus estimate of $492.21 million. During the same period in the prior year, the firm posted $0.51 EPS. The firm’s revenue was down 8.6% compared to the same quarter last year. As a group, research analysts predict that Qiagen will post 2.07 earnings per share for the current fiscal year.
Qiagen Profile
QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.
Featured Articles
- Five stocks we like better than Qiagen
- How to Invest in Cannabis, Step by Step
- Dollar Tree Won’t Be Trading At a Discount For Much Longer
- How to Invest in Esports
- ASML Holding is a Great Buy but at a Cheaper Price
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Oversold and Overextended, Abbott Laboratories is a Great Buy
Want to see what other hedge funds are holding QGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Qiagen (NYSE:QGEN – Free Report).
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
